Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VXCO-100 in Adults in the Republic of South Africa

NCT05938075 is registered in ClinicalTrials.gov with Vaccine Company, Inc. as lead sponsor.

NCT NCT05938075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05938075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VXCO-100 in Adults in the Republic of South Africa
Lead sponsor
Vaccine Company, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 4, 2023
Completion date
July 25, 2024
Enrollment
130 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov, sars-cov-2